TURNING PT THER (TPTX)
(Delayed Data from NSDQ)
$32.54 USD
-1.16 (-3.44%)
Updated May 3, 2019 04:00 PM ET
After-Market: $32.56 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[TPTX]
Reports for Purchase
Showing records 1 - 20 ( 192 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Industry: Medical - Drugs
Bristol-Myers Squibb Makes All-Cash Tender Offer; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Drugs
It''s Friday and TPTX Is in Love; Downgrade to N
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
Repotrectinib Granted Another BTD by FDA; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Drugs
Industry: Medical - Drugs
Nature Paper Provides Validation for Claudin18.2 Target; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Drugs
Industry: Medical - Drugs
Claudin18.2-Targeted ADC In-Licensed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Industry: Medical - Drugs
Turns Attention to Claudin18.2 with ADC Deal
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
Turning Point Partners with ADC Biotech, Decreasing Platform Risk
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Zai Announces Plans for Pre-NDA Meeting for ROS1 NSCLC with the CHA in 4Q
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z